A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Ascending Subcutaneous Doses of SAR441255 in Lean to Overweight Adult Subjects
Latest Information Update: 02 Nov 2021
At a glance
- Drugs SAR 441255 (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Adverse reactions; First in man
- Sponsors Sanofi
Most Recent Events
- 25 Aug 2020 New trial record